Thymosin alpha 1 peptide/polymer conjugates
View Patent ↗A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
1. A pharmaceutical composition comprising a physiologically active conjugate, said conjugate comprising a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases the half-life of the TA1 peptide in serum of a patient when said conjugate is administered to a patient, wherein said material which increases half-life is a polyalkylene oxide polymer.
2. The composition of claim 1 wherein said material is a substantially non-antigenic polymer.
3. The composition of claim 2 wherein said polymer is PEG.
4. The composition of claim 3 wherein said PEG has a molecular weight within a range of about 200-300,000.
5. The composition of claim 4 wherein said molecular weight is about 5,000-35,000.
6. The composition of claim 5 wherein said molecular weight is about 20,000.
7. The composition of claim 2 wherein said polymer is conjugated to an N-terminal portion of the TA1 peptide.
8. The composition of claim 1 wherein said TA1 peptide is TA1.
9. A method of forming a composition as claimed in claim 2 , comprising conjugating a substantially non-antigenic polymer to a Thymosin alpha 1 peptide.
10. The method of claim 9 wherein the polymer is conjugated to an N-terminal portion of the Thymosin alpha 1 peptide.
11. The method of claim 9 wherein the polymer is PEG.
12. The method of claim 9 wherein said PEG has a molecular weight in a range of about 200-300,000.
13. The method of claim 12 wherein said molecular weight is about 5,000-35,000.
14. The method of claim 13 wherein said molecular weight is about 20,000.
15. The method of claim 9 wherein said Thymosin alpha 1 peptide is TA1.
16. A pharmaceutical composition comprising a physiologically active conjugate, said conjugate comprising Thymosin alpha 1I (TA1) peptide conjugated to a substantially non-antigenic PEG which increases the half-life of the TA1 peptide in serum of a patient when said conjugate is administered to a patient.
17. The composition of claim 16 wherein said PEG has a molecular weight within a range of about 200-300,000.
18. The composition of claim 17 wherein said molecular weight is about 5,000-35,000.
19. The composition of claim 18 wherein said molecular weight is about 20,000.
20. The composition of claim 16 wherein said PEG is conjugated to an N-terminal portion of the TA1 peptide.
21. The composition of claim 16 wherein said TA1 peptide is TA1.
22. A method of forming a composition as claimed in claim 16 , comprising conjugating substantially non-antigenic PEG to a Thymosin alpha 1 peptide.
23. The method of claim 22 wherein the PEG is conjugated to an N-terminal portion of the Thymosin alpha 1 peptide.
24. The method of claim 23 wherein said PEG has a molecular weight in a range of about 200-300,000.
25. The method of claim 24 wherein said molecular weight is about 5,000-35,000.
26. The method of claim 25 wherein said molecular weight is about 20,000.
27. The method of claim 22 wherein said Thymosin alpha 1 peptide is TA1.
28. The composition of claim 1 , wherein said material which increases half-life is conjugated to the N-terminal end of said peptide.
29. The method of claim 15 , wherein said material which increases half-life is conjugated to the N-terminal end of said peptide.
30. A composition comprising a conjugate, said conjugate comprising a Thymosin alpha 1 peptide having a PEG with a molecular weight of about 20,000 conjugated to the N-terminal end of said peptide.
31. A pharmaceutical composition comprising a physiologically active conjugate, said conjugate comprising a Thymosin alpha 1 (TA1) peptide conjugated to a PEG having a molecular weight of about 20,000 conjugated to the N-terminal end of said peptide.